|9/19/2018||Changes in responsibility areas of the Orion Group Executive Management Board|
|7/18/2018||Orion Group Half-Year Financial Report January-June 2018|
|7/18/2018||Orion Corporation's financial reporting and Annual General Meeting in 2019|
|4/24/2018||Orion Group Interim Report January-March 2018|
The Closing of the transaction took place on 30 April 2018.
The 2018 Annual General Meeting of Orion was held on Tuesday, 20 March 2018 in Helsinki.
|9/17/2018||Creation of novel medicines and better patient care for the future in an ecosystem|
|9/10/2018||Johanna Ivaska has been appointed Head & Vice President of Oncology Research in Orion Corporation|
|7/6/2018||Orion has started a Phase III trial to develop a drug for ALS - The patient recruitment has begun|
|7/5/2018||Publishing of Orion Corporation's Half-Year Financial Report for January-June 2018 on 18 July 2018|
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs, contract manufacturing and diagnostic tests.
Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.
Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.